Knuff & Co LLC bought a new position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the second quarter, Holdings Channel reports. The firm bought 16,438 shares of the biopharmaceutical company’s stock, valued at approximately $947,000.
Several other institutional investors also recently bought and sold shares of BMY. Swiss RE Ltd. acquired a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $25,000. Physician Wealth Advisors Inc. grew its stake in shares of Bristol Myers Squibb by 73.5% during the 4th quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 202 shares during the period. Darwin Wealth Management LLC purchased a new position in shares of Bristol Myers Squibb during the 2nd quarter valued at approximately $25,000. Bayban acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $31,000. Finally, EQ Wealth Advisors LLC acquired a new position in shares of Bristol Myers Squibb in the 4th quarter valued at $32,000. 76.41% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
BMY has been the topic of several analyst reports. Raymond James Financial began coverage on shares of Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating on the stock. Wall Street Zen upgraded Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Jefferies Financial Group lowered Bristol Myers Squibb from a “buy” rating to a “hold” rating in a research report on Wednesday, August 5th. Piper Sandler initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued an “overweight” rating on the stock. Finally, Citigroup reissued a “neutral” rating and issued a $70.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Bristol Myers Squibb has a consensus rating of “Moderate Buy” and an average price target of $66.06.
Bristol Myers Squibb Price Performance
NYSE:BMY opened at $67.59 on Thursday. The stock has a 50 day moving average of $60.18 and a two-hundred day moving average of $59.24. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $68.64. The firm has a market cap of $138.06 billion, a P/E ratio of 14.89, a price-to-earnings-growth ratio of 0.17 and a beta of 0.22. The company has a current ratio of 1.53, a quick ratio of 1.38 and a debt-to-equity ratio of 1.89.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The business’s quarterly revenue was up 5.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.46 earnings per share. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.95 earnings per share for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were issued a $0.63 dividend. The ex-dividend date was Thursday, July 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.
Bristol Myers Squibb Company Profile
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Featured Stories
- Five stocks we like better than Bristol Myers Squibb
- Bloom Energy’s AI Surge Meets a Valuation Reality Check
- Target Is Winning Shoppers Back—Can the Rally Reach $180?
- IonQ’s Space Contract Points to a New Frontier for Quantum Investors
- Is Apple’s AI Strategy Smarter Than Skeptics Think?
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
